Logo Logo
Exportieren als [RSS feed] RSS 1.0 [RSS2 feed] RSS 2.0
Gruppiert nach: Dokumententyp | Veröffentlichungsdatum
Anzahl der Publikationen: 6

Zeitschriftenartikel

Hofstetter, Kerstin; Taugner, Julian ORCID logoORCID: https://orcid.org/0000-0003-1473-1202; Käsmann, Lukas; Mansoorian, Sina; Flörsch, Benedikt; Eze, Chukwuka; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus ORCID logoORCID: https://orcid.org/0000-0002-1287-7825 und Manapov, Farkhad (2023): First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis. In: Strahlentherapie und Onkologie [Forthcoming] [PDF, 465kB]

Käsmann, Lukas; Eze, Chukwuka; Taugner, Julian; Nieto, Alexander; Hofstetter, Kerstin; Kröninger, Sophie; Guggenberger, Julian; Kenndoff, Saskia; Flörsch, Benedikt; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus ORCID logoORCID: https://orcid.org/0000-0002-1287-7825 und Manapov, Farkhad (2023): Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study. In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 10: S. 7393-7403 [PDF, 1MB]

Taugner, Julian; Käsmann, Lukas; Karin, Monika; Eze, Chukwuka; Flörsch, Benedikt; Guggenberger, Julian; Li, Minglun; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus und Manapov, Farkhad (2022): Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition. In: Investigational new drugs, Bd. 40: S. 163-171 [PDF, 1MB]

Flörsch, Benedikt; Taugner, Julian; Käsmann, Lukas; Kenndoff, Saskia; Guggenberger, Julian; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus; Eze, Chukwuka und Manapov, Farkhad (2022): Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy +/- immune checkpoint inhibition: a decade-long single-center historical analysis. In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 7: S. 3267-3276 [PDF, 1MB]

Käsmann, Lukas; Taugner, Julian; Eze, Chukwuka; Nieto, Alexander; Pelikan, Carolyn; Flörsch, Benedikt; Kenndoff, Saskia; Hofer, Thomas P.; Nössner, Elfriede; Schulz, Christian; Unterrainer, Marcus; Tufman, Amanda; Klauschen, Frederick; Jung, Andreas; Neumann, Jens; Kumbrink, Jorg; Reinmuth, Niels; Bartenstein, Peter; Belka, Claus und Manapov, Farkhad (2022): Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study. In: Translational Lung Cancer Research, Bd. 11, Nr. 7: S. 1503-1509 [PDF, 294kB]

Taugner, Julian; Käsmann, Lukas; Karin, Monika; Eze, Chukwuka; Flörsch, Benedikt; Guggenberger, Julian; Li, Minglun; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus und Manapov, Farkhad (2021): Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition. In: Investigational New Drugs, Bd. 40, Nr. 1: S. 163-171

Diese Liste wurde am Sat Dec 21 23:43:36 2024 CET erstellt.